Purpose. Among the pneumococcal proteins, pneumococcal surface protein A (PspA) is considered the most promising candidate for a serotype-independent vaccine. This study aimed to investigate the serotype, genetic diversity of PspA, lineage (genotype) and drug resistance traits of pneumococcal isolates from paediatric patients.
INTRODUCTION
Streptococcus pneumoniae is responsible for several invasive and non-invasive pneumococcal diseases (IPD and non-IPD) worldwide, such as bacteraemia, meningitis, pneumonia and otitis media [1] . The polysaccharide-protein conjugate-based vaccines (PCVs), namely PCV 7 (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and PCV13 (all PCV7 serotypes plus six extra serotypes, 1, 3, 5, 6A, 7F and 19A), have been shown to be effective for IPD/non-IPD among both children and adults in the USA [2] , and therefore many countries have now implemented pneumococcal vaccination programmes for children. However, the emergence of and increase in non-vaccine types (NVTs) following the introduction of PCV through serotype replacement and capsule switch vaccine escape mutations are a global public health concern [3] [4] [5] .
In Japan, following the introduction of PCV7 in 2010 and then PCV13 in 2013 for children aged under five years, a rapid replacement of vaccine serotypes with NVTs in pneumococcal diseases was observed [6, 7] . In our study following the PCV13 period in 2014, four years after the immunization with PCVs, 78.8 % of all isolates from children with non-IPD were NVTs [8] . Due to the limited number of serotypes that can be included in current PCV vaccine formations for technical and economic reasons, various protein antigenic targets have been proposed for future pneumococcal vaccines [9, 10] .
In regard to the development of novel pneumococcal vaccines that are independent of serotype, pneumococcal surface proteinA (PspA) encoded by the pspA gene has been investigated as an important vaccine antigen because of its capability of inducing protection in different animal models [11] [12] [13] . The clade-defining region (CDR), located at the C-terminus a-helical domain of PspA, contains cross-protective epitopes among different PspA molecules [14] . One previous study showed that immunization with a single recombinant PspA including the a-helical region induced antibodies to heterologous PspA molecules in healthy adults [15] . The PspA protein is classified into three families that are further discriminated into six clades: PspA family1 (clades 1 and 2), PspA family 2 (clades 3, 4 and 5) and PspA family 3 (clade 6). CDRs showing <45 % amino acid sequence differences are assigned to the same family, while those showing <20 % differences are assigned to the same PspA clade [16] . Previous epidemiological studies on children with IPD/non-IPD in the USA [17, 18] and China [19] showed that families 1 and 2 were predominant, accounting for >96 % of pneumococcal isolates, whereas the remaining few isolates were either non-typeable or not classified as PspA family 3. However, available data on the prevalence of PspA and genetic diversity in CDR among NVTs are limited. Furthermore, in particular, prevalence of family 3 has not been clearly demonstrated because of extremely low detection rate.
Verification derived from PspA sequence data in different countries provided useful information relevant to future studies on vaccine development [20] . However, no such evidence based on CDR sequences has been reported to date in Japan. In the present study, we investigated the distribution of PspA families and its relevance to serotypes, and antimicrobial resistance among paediatric non-IPD pneumococcal isolates in Japan. Furthermore, the sequence diversity of CDR in the PspA clade/family in NVTs was analysed.
METHODS

Pneumococcal strains
A total of 678 non-IPD isolates (i.e. isolates from nasal discharge, sputum or other non-sterile sites) were analysed [358 (52.8 %) male, 320 (47.2 %) female]. All isolates were collected from paediatric outpatients (apart from one inpatient) under the age of 16 years (median age, 2.0 years; mean ±SD, 2.9±2.4 years) from various hospitals and clinics throughout Hokkaido prefecture in Japan between June and November 2016. All isolates included only one pneumococcal isolate per patient, and were identified based on colony morphology, alpha haemolysis and the optochin susceptibility test as previously described [21] , which are the identification criteria for S. pneumoniae. Isolates were maintained as frozen stocks in Microbank (Pro-lab Diagnostics, Richmond Hill, Canada) at À80 C until processing. In all experiments, pneumococci were cultured at 37 C in 5 % CO 2 on Trypticase soy agar with 5 % sheep blood agar (Nippon Becton Dickinson).
Serotype assignment by genetic methods Genomic DNA was extracted from individual isolates using a previously described method [22] and stored at 4 C until used as the template in all PCR reactions. Serotypes of all collected pneumococcal isolates were assigned by PCRbased assay targeting the cps locus (sequential multiplex PCR, SM-PCR) following the protocols described on the CDC website (https://www.cdc.gov/streplab/pcr.html) [23, 24] . Primers for the capsular polysaccharide biosynthesis gene A (cpsA) were included in each reaction. Following PCR, subtyping for serogroups 6 and 15 was performed by M-PCR combined with PCR-RFLP and direct DNA sequencing of PCR-amplified products, respectively, as described previously [8, 25, 26] . For isolates assigned to serotypes 33F/33A/37 by SM-PCR, nucleotide deletion in the wcjE gene (serotype 33F [27] ) and the presence of the tts gene (serotype 37 [28] ) were analysed to discriminate these serotypes. Serotypes 35B and 35D were distinguished by sequence differences in the wciG gene [29] . Nucleotide sequences of genes wcjE and wciG were determined by PCR and direct sequencing using primers designed in this study (Table S1 , available in the online version of this article).
All PCRs for serotyping were performed in a volume of 25 µl that consisted of 2.5 µM of 10ÂEx Taq buffer, 200 µM of dNTP, 0.5-2.0 µM of each primer, 0.25 U of Ex Taq DNA polymerase (Takara Bio, Japan) and 2 µl DNA template according to PCR conditions described in the references shown above. After amplification, PCR products were directly separated in 2 % agarose gel. For sequencing, PCR products were sequenced using a BigDye Terminator v3.1 Cycle Sequencing kit on an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems).
Classification of PspA and MLST Classification of the PspA family and clade was performed for all isolates by PCR and DNA sequencing methods, respectively, as described previously by Hollingshead et al. [13, 16] . In the present study, five isolates were selected randomly from each PspA families 1, 2 and/or 3 from individual non-PCV serotypes after the classification of PspA family types. When the number was less than five, all isolates were included in the analysis. For example, for serotype 15A, three (n=3/3) isolates in family1 and five (n=5/95) isolates in family 2 were selected. To determine genetic relatedness, both sequence analyses of CDR in the pspA gene and multi-locus sequence typing (MLST) were performed for all selected isolates. The amplified pspA gene products were sequenced using PCR primers [13] based on the sequence method described above. Using BLAST (http://www.ncbi. nlm.nih.gov/BLAST/) search and the ClustalW (http:// www.ebi.ac.uk/clustalw/) program, the nucleotide sequence data obtained were compared to the corresponding DNA sequences of 74 pneumococcal strains from the GenBank database, as reported previously [16, [30] [31] [32] [33] [34] . Phylogenetic trees with maximum-likelihood methods (the Kimura twoparameter model) were constructed utilizing MEGA 6.0 software [35] . The trees were statistically supported by bootstrapping with 1000 replicates. MLST was also performed on the isolates, according to the S. pneumoniae MLST protocol using the methods and primers for the seven housekeeping genes described on the MLST website (https:// pubmlst.org/). Using this website, the allele number and ST were assigned and new allelic profiles with isolate information for new ST assignment were submitted. STs were compared to the Pneumococcal Molecular Epidemiology Network (PMEN) international clones (http://web1.sph. emory.edu/PMEN), which provides STs with globally resistant and susceptible clones known to be important. The partial CDR sequences of the isolates in the present study were deposited in the Gene Bank database under accession numbers MG775436-775450 (Table S2) .
Antimicrobial susceptibility testing and detection of drug resistance genes Antimicrobial susceptibility was measured by broth microdilution test using Dry Plate Eiken HW04 (Eiken, Tokyo, Japan), measuring MIC within a limited concentration range for all isolates of predominant serotypes 35B, 15A, 15C and 23A. MICs were determined for 16 antimicrobials:
, vancomycin (VAN), tetracycline (TET) and trimethoprim-sulfamethoxazole (SXT). S. pneumoniae ATCC 49619 was used as a quality control strain. MIC interpretations were based on the Clinical and Laboratory Standards Institute (CLSI) breakpoint criteria [36] . For interpretation of the breakpoints of PEN, FEP, CRO and CXM, the CLSI criteria for oral administration were used. In the present study, multidrug resistance (MDR) was described as including two categories, MDR and PEN-MDR, which represent resistance to three or more different antimicrobial classes [37] and non-susceptibility to PEN (MIC, !0.12 µg ml À1 ) combined with resistance to two or more other antimicrobial classes [38] , respectively.
The erm(B) and mef(A/E) genes, determinants of macrolide resistance, were detected by M-PCR for all isolates as described previously [39, 40] .
Statistical analyses
All statistical analyses were performed using SPSS 19.0 (IBM, Armonk, NY). Two-tailed chi-square test or Fisher's accurate probability methods (for small group sizes) were used to assess correlations between the prevalence of PspA and resistance genes. P-value of less than 0.05 was considered significant.
RESULTS
Distribution of serotypes and PspA families
The proportion of PspA families in individual serotypes is shown in Table 1 . In this study, non-vaccine types (NVTs) were defined as serotypes not included in PCV13. Among all isolates, 596 (87.9 %) belonged to NVTs and the prevailing serotypes were NVTs 15A (14.5 %), 35B (11.8 %), 15C (9.3 %), 23A (9.0 %), 10A, 15B, 11A/11D and 34, accounting for 74.3 % of all isolates. Serotypes included in PCVs, i.e. vaccine types (VTs) 4, 6B, 9V, 14, 18C, 1 and 5, were not detected. Among the 678 isolates, 671 (99.0 %) had PspA belonging to either family 1 (42.3 %; 287/678) or 2 (56.6 %; 384/678), while four isolates (0.6 %) had family 3 PspA, but the remaining three isolates (0.4 %) were pspA-negative. Overall, 99.6 % of all isolates had PspA that was assigned to one of the three families. In regard to VTs and NVTs, no significant difference was observed for detection rates of PspA families 1 and 2 (P=0.2311).
All the isolates of serotypes 3, 23A, 10A, 34, 24, 22F/22A, 33F, 23B and 38 expressed family 1 PspA, whereas serotypes 
DISCUSSION
The present study elucidated pneumococcal serotypes and their relationship to the genetic diversity of PspA families/ clades and MLST sequence types among non-invasive isolates from children, six years after the introduction of paediatric immunization with PCV in Japan. The overall rate of non-PCV13 serotypes (NVTs) in this study was 87.9 %, which is similar to that observed in recent studies from other Asian countries [5, 41] . Our study also revealed high rates of MDR in isolates of predominant NVTs 15A, 35B and 23A (96.9, 81.3 and 100 %, respectively) that showed resistance to penicillin, erythromycin and tetracycline. There has been little variation in NVTs since a previous study in 2014 [8] , indicating limited spread of these serotypes among children in Japan. One previous nationwide population-based surveillance study, from 2008 to 2013 (pre-to post-PCV7 periods), in Japan demonstrated a 98 % reduction in the incidence rate of paediatric IPD caused by PCV7 serotypes associated with serotype replacement and significant increase of non-susceptibility isolates to meropenem, particularly in NVT 15A after the use of PCV7 [42] . Hence, an increase in NVTs associated with a high prevalence of MDR is now of potential concern in pneumococcal diseases in Japan.
PspA is an important vaccine candidate as a common protein antigen, because it provides serotype-independent protection against pneumococcal diseases [43, 44] . Most of the clinical isolates of pneumococci (94.0-99.9 %) express PspA family 1 (clades 1 and 2) or PspA family 2 (clades 3, 4 15A ( and 5), as documented in previous studies in the USA [17, 18, 45] , France [10] , China [19] and Japan [46] . However, PspA family 3 was not detected in these studies. In the present study, PspA family 3 was detected in four isolates (0.6 %) of serotype 37, which were all assigned to clade 6.
To date, little information is available on the CDR of PspA family3/clade 6 in pneumococci [16, 47, 48] , while one Japanese study showed that PspA family 3 (serotypes 15B, 23F and others) was identified in 3.4 % of pneumococcal isolates [49] . Of note, serotype 37, which had been described as Fig. 1 . Phylogenetic tree of PspA family 1 (clades 1 and 2) based on clade-defining region (CDR) sequences. CDR sequences of the 37 pneumococcal isolates utilized in this study and the 39 reference strains from GenBank described in previous studies [16, [30] [31] [32] [33] were used to construct the phylogenetic tree by the maximum-likelihood method. Filled circles and squares indicate isolates analysed in the present study. Bootstrap values >90 % are shown. The scale bar shows the genetic distance.
serotype 33F/33A/37 by SM-PCR, was detected in our previous surveillance studies at rates of 0.8 % in 2011 [25] and 1.3 % in 2013/2014 [7] . All four serotype 37 isolates with family 3/clade 6 had CDR sequences identical to the two sequences (GenBank accession nos. AF071823 and LT669651) reported from studies in the USA [16, 47] . Thus, despite its low frequency, PspA clade 6 seems to be genetically highly conserved in pneumococci. Moreover, MLST analysis demonstrated that all serotype 37 isolates belonged to ST447 or SLV of this ST, suggesting that a single serotype 37/ST447 clone with PspA clade 6 had occurred in Japan following the use of PCVs. It is remarkable that all serotype 37 isolates in the present study were confirmed as forming a mucoid phenotype when grown on blood agar, as CDR sequences of the 34 pneumococcal isolates in this study and the 32 reference strains from GenBank described in previous studies [16, [30] [31] [32] 34] were used to construct the phylogenetic tree by the maximum-likelihood method. Filled circles, squares and diamonds indicate isolates analysed in the present study. Bootstrap values >90 % are shown. The scale bar shows the genetic distance.
reported previously [28] . Because mucoid strains are associated more with various local infections than non-mucoid strains [50] , it will be necessary to monitor the prevalence of serotype 37 isolates expressing PspA clade 6 in the post-PCV13 era.
The present study showed that most pneumococcal isolates (99 %) belong to either PspA family 1 or 2, depending on serotype. Although some serotypes (VTs 19F, 23F and NVTs 15A and 6C) were associated with both families, PspA family 1 was detected in all isolates of prevalent VT 3 and in NVTs 10A, 22F/22A, 23A, 23B, 24, 33F, 34 and 38. In contrast, family 2 PspA was found in VTs 6A, 7F and 19A and in NVTs 11A/11D, 15B, 15C and 35B. Previous studies also showed similar results for the association of PspA family 1 with serotypes 10A and 23A, and PspA family 2 with serotypes 19A and 11A/11D, among isolates from adults in Japan [46] . A study in the USA showed an association of PspA family 1 with certain serotypes (23F, 10A, 23A and 23B) from IPD and non-IPD among children [18] . Taken together, pneumococcal serotypes are considered to be correlated with PspA family type. In conclusion, our study revealed the persistently high prevalence of non-PCV13 serotypes with genetically divergent PspA in S. pneumoniae isolates following PCV use in Japan. Although most isolates were found to express family 1 or 2 PspA, family 3 PspA was detected in serotype 37 isolates forming mucoid colonies. Three isolates were negative for PspA by PCR, which is suggested to be due to the lack or nucleotide sequence diversity of the pspA gene. Accumulation of epidemiological information, including the prevalence of serotypes in the PspA family/clade, are important in the design of vaccines based on PspA, and thus further detailed study may be necessary in regard to PspA-negative/ divergent isolates. Our observations may provide the foundation for the future development of multi-component PspA-based pneumococcal vaccines.
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